A new proof-of-concept study by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) shows that changing only a single letter in the DNA code of selected genes in T cells may lead to improved cell therapy. The researchers, led by Benjamin Izar, a member of the HICCC, used novel CRISPR-dependent base editing to "supercharge" cell therapies, making them potentially more effective for more patients.